Sunho Biologics

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing.

Sunho Biologics gets green light for downsized IPO

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…

Recent Articles

RELATED ARTICLES

  1. With no product or licensing revenue, Sunho Biologics has been piling up debts from high R&D spending.
    Funding boost gets Sunho Biologics over the IPO filing line
  2. Cash-strapped Viva Biotech sells stake and plans spinoff
    1873.HK
  3. WuXi Biologics hatches new baby with ADC drug unit IPO
    2269.HK
  4. GenScript losses shrink on strong growth for cancer cell therapy 
    1548.HK
  5. New Horizon Health finds formula for profits ahead of schedule
    6606.HK
  6. Payment app Lianlian seeks IPO relief from cash crunch
  7. Akeso marks profit milestone with swift rights issue
    9926.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva